Ovagen: Scientific Profile

Publicado el 12 de julio de 2026 · Actualizado el 24 de agosto de 2026

Ovagen is a short tripeptide (Glu-Asp-Leu, EDL) of the family of peptide bioregulators described by the Khavinson group, studied in research models for its association with hepatic and digestive function. It is proposed as a regulatory peptide that would modulate protein synthesis in specific tissues; its independent evidence is limited and largely preclinical.

Ovagen is a short synthetic peptide composed of three amino acids —glutamic acid, aspartic acid, and leucine (Glu-Asp-Leu, abbreviated EDL)— that belongs to the family of so-called short peptide bioregulators developed and characterized mainly by the research group of Vladimir Khavinson in Saint Petersburg. This line of compounds arose from a program that sought low-molecular-weight peptide fragments derived from tissue extracts, with the hypothesis that very short sequences could act as "tissue-specific" regulatory signals. Ovagen is studied in this context as a peptide classically associated with the function of the female reproductive system (ovarian tissue), although it should be emphasized from the outset that, as with other bioregulators of this group, there is no CAS number assigned in public databases, and that the formula and molecular weight values listed alongside this sheet correspond to the calculated Glu-Asp-Leu tripeptide, not to a characterization independently consolidated outside its group of origin.

As for its structure, the sequence Glu-Asp-Leu is the defining feature of the compound and coincides with the synonym EDL used in the bioregulator literature. It is a tripeptide, so structurally it is a small molecule, hydrophilic in its first two residues (both dicarboxylic acids) and with a terminal leucine residue of apolar character. This combination of charged residues and a hydrophobic residue is a recurring signature in several bioregulators of the same family (for example, other tri- and tetrapeptides with glutamate and aspartate). The brevity of the sequence should not be confused with a complete physicochemical characterization: for Ovagen, unlike better-described research peptides, there is no CAS registry or consolidated identity record established independently outside its group of origin.

The proposed mechanism of action for Ovagen falls within Khavinson's general hypothesis of short peptide bioregulators. According to that hypothesis, certain di-, tri- and tetrapeptides could penetrate the cell and even the nucleus and interact with specific regions of DNA or chromatin, selectively modulating the expression of particular genes and, with it, protein synthesis in the corresponding tissue. For Ovagen in particular, this group's work links it with the normalization of functional parameters of ovarian tissue in experimental models, proposing that it would act as a regulatory signal that would favor the homeostasis of the female reproductive system. It is important to be clear about the status of this explanation: the model of "peptide binding to DNA with tissue-specific gene regulation" is a working hypothesis of the originating group itself and does not have broad, independent mechanistic validation. Therefore, the mechanism should be presented as proposed and not as established.

The documented research applications for Ovagen concentrate on preclinical models and on studies associated with the group that developed it, aimed at exploring its effect on markers of ovarian function, protein synthesis, and reproductive hormonal parameters, as well as on general indicators of tissue aging that motivate the classification of the family as "anti-aging" bioregulators. Within this framework, the experimental interest lies in using it as a tool to study whether ultra-short peptide sequences can induce reproducible changes in the activity of specific tissues. However, the evidence base is limited: much of the data comes from a single research group, with little external replication, an absence of large-scale controlled peer-reviewed clinical trials outside that setting, and a still nascent pharmacokinetic and pharmacodynamic characterization. There is no regulatory approval supporting an established therapeutic use, and claims about efficacy must be treated with caution.

Because of its tripeptide nature and its classification within the bioregulators of the Khavinson family, Ovagen is usually grouped conceptually with other short peptides of the same series that nominally target different organs or systems. This membership in a "group" is useful for contextualizing the compound, but it also implies that it shares with its congeners the same essential limitation: independent, high-quality evidence is scarce. In summary, Ovagen is a short peptide (Glu-Asp-Leu) of interest in exploratory research on the tissue regulation of the female reproductive system (ovarian tissue), with a proposed —unconfirmed— mechanism of modulation of gene expression, and with a level of evidence that must honestly be characterized as limited and predominantly preclinical or restricted to its group of origin.

This material is described exclusively for research purposes and for use in laboratory research. The parameters of handling, storage and experimental work that are mentioned correspond to the context of a controlled research environment.